Business Wire

Innocoll Announces Publication of Positive Results from Pivotal Clinical Trial of POSIMIR in Arthroscopic Subacromial Decompression

POSIMIR ® (bupivacaine solution) for infiltration use reduced mean pain over 72 hours after arthroscopic subacromial decompression surgery compared with vehicle control and improved several measures ...
Nasdaq

DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression

CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved POSIMIR® (bupivacaine solution) for ...
Medscape

Shoulder Decompression No Better Than Placebo Surgery

Arthroscopic subacromial decompression surgery does not reduce pain any more than arthroscopy alone in people with shoulder impingement, researchers say. "[T]he findings from our study suggest that ...
aafp.org

Surgery Equal to No Surgery for Patients with Subacromial Shoulder Pain

Professor, Michigan State University, East Lansing, Mich. These authors randomized adults with subacromial pain of at least three months' duration into one of three groups: arthroscopic decompression ...
Monthly Prescribing Reference

Posimir Now Available for Postsurgical Analgesia Following Shoulder Surgery

Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered directly into the surgical site. Posimir ® (bupivacaine solution) is now available for ...